Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. sap-nano

SAP-Nano

A disruptive technology for vaccines manufacturing based on Self-Assembled Polymeric Nanoparticulate systems

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 SAP-Nano project word cloud

Explore the words cloud of the SAP-Nano project. It provides you a very rough idea of what is the project "SAP-Nano" about.

evaluation    sme    economic    ensures    point    swine    25    2015    first    solved    commercial    easily    thorough    molecules    21    impossible    12    costly    instrument    nanotechnology    viability    opportunity    standard    manufacturer    marketing    antigens    met    performed    scalability    presented    manufacturing    feasibility    strategies    score    perform    manufacturers    fish    inexpensive    organic    seemed    company    pharmaceutical    suitable    industry    nanoparticle    sap    firstly    patented    model    versatile    11    veterinary    usa    million    market    risks    avoiding    scalable    requirement    significantly    vaccines    losses    move    time    techniques    encapsulate    84    nano    faced    submission    successfully    prrsv    verify    usd    cosmetic    laboratory    eur    clients    detected    billion    nmp    bionanoplus    lower    issue    launch    total    business    plan    volatile    conventional    solvents    minimize    664    industrial   

Project "SAP-Nano" data sheet

The following table provides information about the project.

Coordinator		 BIONANOPLUS SL 

Organization address
address: POLIGONO MOCHOLI, PLAZA CEIN 5
city: NOAIN
postcode: 31110
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Spain [ES]
 Project website http://www.bionanoplus.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing)
2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-06-01   to  2016-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIONANOPLUS SL ES (NOAIN) coordinator 50˙000.00

Map

 Project objective

Bionanoplus detected the major problems faced by many pharmaceutical, veterinary and cosmetic sector manufacturers to develop products using nanotechnology. It seemed impossible and costly to move a product developed in the laboratory to the industrial manufacturing of the product. To solve this issue Bionanoplus has developed and patented a highly versatile and easily scalable technology to encapsulate antigens and other molecules, called SAP-Nano. Bionanoplus has solved the scalability problem of traditional nanoparticle manufacturing methods avoiding the use of volatile organic solvents, thus it ensures an easy and inexpensive production of any scale, which can be performed using standard equipment and techniques. SAP-Nano technology has been successfully implemented with two clients, a fish vaccines manufacturer and a pharmaceutical company. Now Bionanoplus plan to launch his technology in the vaccines manufacturers market, firstly on to the PRRSV vaccines manufacturers market. It was estimated that losses due to PRRSV cost the swine industry EUR 1.5 billion per year in Europe and USD 664 million per year in the USA. SAP-Nano enables the development of unique vaccines, which are significantly more effective than conventional vaccines. Phase 1 of SME Instrument represents an opportunity to get a thorough business plan to minimize risks. The main objective is to perform a feasibility study to verify the economic viability in the vaccines manufacturers market and design a suitable business model, and the commercial, marketing and industrial strategies. The SAP-Nano proposal was presented for the first time to the 25-11-2015 call (NMP-25-2015-1-P) achieving a total score of 12,84. The lower point in the evaluation was Impact (score: 4.21). B has met potential clients in order to know the needs and requirement to develop new vaccines. The business case has also been improved. This new information has been included in this new submission of the proposal.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SAP-NANO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SAP-NANO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.5.;H2020-EU.2.1.3.;H2020-EU.2.3.1.;H2020-EU.2.1.2.)

NAS (2018)

Nexilis augmentation system

Read More  

Gri3D (2018)

The industrialization and market entry of a novel bioengineered hydrogel grid to standardize stem cell cultures for precision medicine.

Read More  

CGM (2018)

A next generation nano media tailored to capture and recycle hazardous micropollutants in contaminated industrial wastewater.

Read More